Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBT (2016 - 2025)

Historic EBT for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $28.3 million.

  • Arrowhead Pharmaceuticals' EBT rose 11614.42% to $28.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $254.9 million, marking a year-over-year increase of 13928.56%. This contributed to the annual value of $51.5 million for FY2025, which is 10841.41% up from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' EBT is $28.3 million, which was up 11614.42% from $36.1 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' EBT ranged from a high of $369.6 million in Q1 2025 and a low of -$179.1 million during Q2 2025
  • Moreover, its 5-year median value for EBT was -$67.7 million (2021), whereas its average is -$51.6 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 36637.3% in 2024, then skyrocketed by 39104.54% in 2025.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' EBT stood at -$62.9 million in 2021, then surged by 33.53% to -$41.8 million in 2022, then crashed by 231.84% to -$138.7 million in 2023, then dropped by 26.26% to -$175.1 million in 2024, then soared by 116.14% to $28.3 million in 2025.
  • Its last three reported values are $28.3 million in Q4 2025, $36.1 million for Q3 2025, and -$179.1 million during Q2 2025.